Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 2;181(1):136-150.
doi: 10.1016/j.cell.2020.03.023.

CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors

Dan Wang  1 , Feng Zhang  2 , Guangping Gao  3
Affiliations
Review

CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors

Dan Wang et al. Cell. .

Abstract

The development of clustered regularly interspaced short-palindromic repeat (CRISPR)-based biotechnologies has revolutionized the life sciences and introduced new therapeutic modalities with the potential to treat a wide range of diseases. Here, we describe CRISPR-based strategies to improve human health, with an emphasis on the delivery of CRISPR therapeutics directly into the human body using adeno-associated virus (AAV) vectors. We also discuss challenges facing broad deployment of CRISPR-based therapeutics and highlight areas where continued discovery and technological development can further advance these revolutionary new treatments.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests D.W. is an inventor on issued patents and patent applications relating to AAV- and CRISPR-based technologies. F.Z. is an inventor on issued patents and patent applications relating to CRISPR-based technologies. F.Z. is a co-founder and scientific advisor of Editas Medicine, Beam Therapeutics, Pairwise Plants, Arbor Biotechnologies, and Sherlock Biosciences. G.G. is an inventor on issued patents and patent applications relating to AAV- and CRISPR-based technologies. G.G. is a co-founder of Voyager Therapeutics and Aspa Therapeutics.

Figures

Figure 1.
Figure 1.. Therapeutic editing strategies based on nuclease activity.
(a) Gene disruption introduces indel mutations (red and orange bars) into a gene (dark gray bars), silencing the gene function, (b) Targeting can be specific to the mutant allele (red bar) and spare the normal allele, (c) HDR mediates precise mutation repair in the presence of a donor template, (d) Targeted insertion of a therapeutic gene (green bar) can be achieved by either HDR or HITI. (e) Two cuts can delete a large gene fragment harboring a mutation, resulting in the production of truncated by partially functional protein, (f) Allelic exchange converts a compound heterozygous genotype to heterozygous through translation between two homologous chromosomes (dashed lines). The targeting site is designed to be intronic, so that the indel mutations caused by DNA repair (yellow bars) do not compromise gene expression, (g) RNA targeting achieves gene silencing by degrading RNA instead of DNA. NHEJ: non-homologous end joining. HDR: homology-directed repair. HITI: homology-independent targeted integration.
Figure 2.
Figure 2.. Cas-effector fusion platforms for therapeutic purposes.
(a) Cas protein (gray shape) fused a transcriptional inhibitor (red oval) or activator (green oval) can repress or boost transcription, respectively, (b) Cas protein fused with an enzyme that can modify epigenetic marks of DNA (blue flags) or histone (brown flag) is useful to change gene expression status, (c) A DNA base editor consists of a dCas or nCas protein, and an adenine or cytosine deaminase (orange oval) that converts A to G or C to T, respectively (red bars to green bars). Note that the editing window (orange shade) may contain by-stander editing targets. An RNA base editor can mediate A to I or C to U base change (red diamond to green diamond), (d) Prime editor comprises an nCas protein fused with a reverse transcriptase (purple oval). Note that the editing window (purple shade) starts from 3 base pairs upstream of the PAM (red bars) of SpCas9, and the editing outcome can be diverse (rainbow shade), including all single base changes and small indels (not shown).
Figure 3.
Figure 3.. Reconstitution of full-length protein expression from two AAV vectors.
(a) The two AAV vector genomes can undergo recombination mediated by an overlapping sequence (1), ITR (2), or a recombinogenic sequence (3) to form a recombined vector DNA that encodes the full-length protein. The transcript derived from the recombined vector DNA may undergo splicing by engineered splicing signals (purple pentagons), (b) The two mRNAs transcribed from individual vector genomes can undergo trans-splicing to form a chimeric mRNA encoding the full-length protein, which is promoted by the hybridization domains (short black bars), (c) The two half proteins expressed from the two AAV vectors can undergo protein trans-splicing mediated by split inteins (diamonds) to form a full-length protein.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, Verdine V, Cox DBT, Kellner MJ, Regev A, et al. (2017). RNA targeting with CRISPR-Cas13. Nature 550, 280–284. - PMC - PubMed
    1. Abudayyeh OO, Gootenberg JS, Franklin B, Koob J, Kellner MJ, Ladha A, Joung J, Kirchgatterer P, Cox DBT, and Zhang F (2019). A cytosine deaminase for programmable single-base RNA editing. Science 365, 382–386. - PMC - PubMed
    1. Adikusuma F, Piltz S, Corbett MA, Turvey M, McColl SR, Helbig KJ, Beard MR, Hughes J, Pomerantz RT, and Thomas PQ (2018). Large deletions induced by Cas9 cleavage. Nature 560, E8–E9. - PubMed
    1. Akcakaya P, Bobbin ML, Guo JA, Malagon-Lopez J, Clement K, Garcia SP, Fellows MD, Porritt MJ, Firth MA, Carreras A, et al. (2018). In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 561, 416–419. - PMC - PubMed
    1. Amoasii L, Long C, Li H, Mireault AA, Shelton JM, Sanchez-Ortiz E, McAnally JR, Bhattacharyya S, Schmidt F, Grimm D, et al. (2017). Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Science translational medicine 9. - PMC - PubMed

Publication types